Chaim Indig Sells 3,089 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) CEO Chaim Indig sold 3,089 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $21.03, for a total transaction of $64,961.67. Following the transaction, the chief executive officer now owns 1,220,647 shares of the company’s stock, valued at approximately $25,670,206.41. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Chaim Indig also recently made the following trade(s):

• On Tuesday, September 10th, Chaim Indig sold 5,295 shares of Phreesia stock. The stock was sold at an average price of $23.25, for a total transaction of $123,108.75.
• On Monday, July 29th, Chaim Indig sold 7 shares of Phreesia stock. The stock was sold at an average price of $24.75, for a total transaction of $173.25.

Phreesia Stock Down 2.2 %

PHR traded down $0.45 during trading on Thursday, hitting $20.40. 434,344 shares of the company’s stock were exchanged, compared to its average volume of 450,865. The business’s 50 day moving average is $23.40 and its two-hundred day moving average is $22.45. The stock has a market cap of $1.17 billion, a P/E ratio of -9.45 and a beta of 0.93. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.03. Phreesia, Inc. has a fifty-two week low of $12.05 and a fifty-two week high of $29.16.

Phreesia (NYSE:PHR) last announced its earnings results on Wednesday, September 4th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.06. The company had revenue of $102.12 million during the quarter, compared to the consensus estimate of $101.76 million. Phreesia had a negative net margin of 25.73% and a negative return on equity of 39.34%. As a group, equities analysts expect that Phreesia, Inc. will post -1.23 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Phreesia

Several institutional investors have recently added to or reduced their stakes in PHR. Wesbanco Bank Inc. bought a new position in Phreesia during the third quarter worth about $593,000. Essex Investment Management Co. LLC raised its stake in shares of Phreesia by 44.7% during the third quarter. Essex Investment Management Co. LLC now owns 117,849 shares of the company’s stock worth $2,686,000 after acquiring an additional 36,406 shares in the last quarter. Inspire Investing LLC purchased a new position in shares of Phreesia during the third quarter worth approximately $416,000. Diversified Trust Co raised its stake in shares of Phreesia by 12.9% during the third quarter. Diversified Trust Co now owns 24,356 shares of the company’s stock worth $555,000 after acquiring an additional 2,782 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Phreesia in the third quarter worth approximately $954,000. Institutional investors own 92.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Robert W. Baird boosted their target price on shares of Phreesia from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Friday, September 6th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $34.00 price objective on shares of Phreesia in a research note on Thursday, September 5th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $23.00 price objective on shares of Phreesia in a research note on Friday, September 27th. JPMorgan Chase & Co. upped their price objective on shares of Phreesia from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Monday, September 9th. Finally, KeyCorp reduced their price objective on shares of Phreesia from $27.00 to $25.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, Phreesia has an average rating of “Moderate Buy” and an average target price of $29.42.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.